Lyme disease trial withdrawn before it even started
NCT ID NCT06785402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to test whether giving the antibiotic ceftriaxone every 5 days for about 6 weeks could kill the bacteria causing persistent Lyme disease symptoms. It planned to enroll people aged 18-75 with Post-Treatment Lyme Disease Syndrome. However, the trial was withdrawn before any participants were enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ceftriaxone
- What this could lead to
- If successful, this could point toward a treatment for persistent Lyme symptoms after standard antibiotics.
- What could go wrong
- The study was withdrawn before enrolling any participants, so no data is available. It is unclear if this approach is safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-TREATMENT LYME DISEASE SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Earthworm enzyme trial aims to ease long covid and chronic fatigue
- Could a malaria drug ease lingering lyme symptoms?
- Can a mask that pulses light and sound ease chronic pain?
- Zapping a nerve in the ear might ease lingering lyme disease symptoms
- Lyme disease mystery: do bacteria lurk after antibiotics?
- Massive study aims to unlock secrets of brain inflammation diseases